Diebold Nixdorf Incorporated (DBD) Stock Price & How to Invest

Diebold Nixdorf makes the machines that move cash and check out shoppers: ATMs, cash recyclers, self-checkout systems, point-of-sale terminals, and kiosks, sold through two segments (Banking and Retail) alongside the Vynamic software suite and a large installed-base services business. It is the global leader in self-checkout shipments outside China and serves a majority of the world's largest banks and retailers, so its revenue is tied to bank branch modernization, cash-recycling adoption, and retail automation cycles rather than any single fast-growing end market.

The investment picture is defined by the company's 2023 financial restructuring. Diebold Nixdorf filed Chapter 11, wiped out much of a crushing debt load, and relisted on the NYSE in August 2023 at roughly $20.57 per share. Since then it has strung together consecutive quarters of positive free cash flow, returned to GAAP profitability, and rebuilt around higher-margin services (now a majority of revenue) and premium DN Series cash recyclers. The stock has re-rated sharply off its emergence price, so the current setup is less about survival and more about whether a mature hardware plus services business can keep expanding margins and free cash flow in a low-single-digit growth market.

In 2026 the numbers have been steady rather than spectacular. Second-quarter revenue was about $931 million, up roughly 2% year over year, and adjusted EPS of $1.10 matched consensus exactly, after a first quarter of about $892 million in revenue and $0.67 of adjusted EPS (versus $0.62 expected). GAAP net income remained thin at about $16 million for the quarter, and trailing-twelve-month revenue is about $3.87 billion with net income of about $111 million. The stock fell about 24% over the three months to mid-October from a high near $92, then rebounded about 7% in the past month; as of October 16, 2026 it closed near $67.44, up about 5% year to date and about 19% over the past year, for a market value near $2.3 billion. Wedbush kept an Outperform rating and $100 target ahead of results, pointing to rising average selling prices, a possible benefit from memory pricing, and the chance to refinance debt at better rates when it becomes callable in December. Third-quarter results are due October 28, 2026, with consensus near $1.31 per share on about $972 million of revenue.

The core hardware markets (ATMs, POS, self-checkout) are mature and grow at low single digits, so structural declines in cash usage and bank branch counts are a persistent headwind. The company competes with well-capitalized rivals like NCR Atleos, NCR Voyix, Hyosung, and Glory, which pressures pricing on commoditizing hardware. Revenue is global with meaningful exposure to Europe and emerging markets, adding currency and macro sensitivity, and lumpy hardware order timing can make any single quarter volatile. Having so recently emerged from Chapter 11, the market is still assessing whether the improved margins are durable, and the stock has already re-rated substantially off its emergence price, leaving less margin for disappointment. Execution missteps on large rollouts or a slowdown in recycler adoption could quickly compress the margin story the valuation now assumes. The stock's roughly 24% slide over the three months to mid-October 2026 shows how quickly sentiment can turn on a quarter that was only in line, and component costs, including memory, are a swing factor in hardware margins.

3 analysts publish price targets on DBD, averaging $98.33 against a $66.83 price as of October 2026, or +47.1%. The published targets run from $95.00 to $100.00, a narrow spread, and the ratings split 3 buy, 0 hold, 0 sell. Over the last six months there have been 0 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full DBD forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Diebold Nixdorf Incorporated. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Services mix and recurring revenue. Services now make up roughly 57% of total revenue at a steady gross margin near the mid-20s, giving the business a more predictable, recurring base than pure hardware sales. The most optimistic published target, $100.00, assumes this works close to its best case.

The case against. The core hardware markets (ATMs, POS, self-checkout) are mature and grow at low single digits, so structural declines in cash usage and bank branch counts are a persistent headwind. The most pessimistic target, $95.00, is roughly what DBD is worth if this bites instead.

Read the full bull and bear case on DBD, including what would have to change to break either one. Walnut is not an investment adviser.

No. Diebold Nixdorf Incorporated (DBD) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Diebold Nixdorf Incorporated's investor relations page or your broker.

• Revenue (TTM): ~$3.87B
• Q2 2026 revenue: ~$931M (+2% YoY); adjusted EPS $1.10 vs $1.10 expected
• Net income (TTM): ~$111M; ~8% operating margin
• 2026 adj. EBITDA guidance: ~$510M to $535M
• 2026 adj. EPS: Guidance ~$5.25 to $5.75; consensus ~$5.37
• Market cap: ~$2.3B at $67.44 (Oct 16, 2026)
• P/E: ~22x trailing, ~9.6x forward
• Balance sheet: ~$1.1B debt, ~$267M cash

DBD trades around a $2.3 billion market cap with the stock near $67, still well above its August 2023 relisting price of about $20.57 but down from a 52-week high near $92. At roughly 9.6 times forward earnings and under 7 times EV to EBITDA, the multiple has compressed from the high-20s P/E the stock carried in mid-2026, so the market is now pricing in less margin expansion. Revenue growth remains modest (low single digits), and the October 28 report is the next check on free cash flow and the second-half ramp.

Other names that sit close to DBD: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get DBD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so DBD sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where DBD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

DBD is a de-levered comeback in physical-commerce hardware where recurring services and higher-value cash recyclers are the whole story, so the durability of that margin trajectory is what matters most. After a pullback from a 52-week high near $92 to about $67 in October 2026, the stock trades near 9.6 times forward earnings, and the October 28 report is the next read on that trajectory.

Whether DBD is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is DBD a buy or a sell?, and where the stock could go from here in the DBD stock forecast.

For income investors, whether DBD pays a dividend and how the payout looks is covered in does DBD pay a dividend? And to weigh DBD against a peer, read the full side-by-side comparisons: DBD vs ORCL and DBD vs FISV.